INGELHEIM, Germany - Monday, June 17th 2013 [ME NewsWire]
Published online in Circulation, results from RELY-ABLE®, the RE-LY® extension study, support long-term safety of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation
Pradaxa® is the only novel oral anticoagulant with controlled long-term clinical trial data extending beyond 4 years of ongoing treatment
The long-term results contribute to the growing body of data reinforcing Pradaxa® as an important advancement in the treatment of patients with atrial fibrillation compared to warfarin1
(BUSINESS WIRE)-- For media outside of the US, the UK & Canada only
New long-term data from the RELY-ABLE® study, the long-term extension of the pivotal RE-LY®i trial of Pradaxa® (dabigatran etexilate) in patients with non-valvular atrial fibrillation (AF), were t
...
Read more »